FILE PHOTO: Signage is seen outside of the Food and Drug Administration headquarters in White Oak, Maryland, U.S., August 29, 2020. REUTERS/Andrew Kelly/File Photo

Biohaven paused new patient enrollment in experimental epilepsy drug trials after the United States Food and Drug Administration imposed a partial clinical hold. Shares fell 15% in early trading following the regulatory action.